Mechanisms of dyslipoproteinemias in systemic lupus erythematosus

Clinical and Developmental Immunology

Volumn 13, Issue 2-4, 2006, Pages 203-208

  Borba, Eduardo F ^a   Carvalho, Jozelio F ^a   Bonfá, Eloísa ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Atherosclerosis; Dyslipoproteinemia; Hyperlipidemia; Inflammation; Lipoprotein; Systemic lupus erythematosus

Indexed keywords

AUTOANTIBODY; C REACTIVE PROTEIN; CARDIOLIPIN ANTIBODY; CORTICOSTEROID; GAMMA INTERFERON; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYCHLOROQUINE; INTERLEUKIN 6; LIPOPROTEIN; LIPOPROTEIN LIPASE; MONOCYTE CHEMOTACTIC PROTEIN 1; OXIDIZED LOW DENSITY LIPOPROTEIN; PREDNISONE; TRIACYLGLYCEROL;

ANTIGEN ANTIBODY COMPLEX; ARTICLE; AUTOIMMUNITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DYSLIPOPROTEINEMIA; ENDOTHELIUM CELL; ENZYME REGULATION; FOAM CELL; HUMAN; INFLAMMATION; LIPID METABOLISM; LIPOPROTEIN METABOLISM; MENOPAUSE; NEPHROTIC SYNDROME; OXIDATIVE STRESS; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; THYROID DISEASE; UREMIA;

HUMANS; HYPERLIPOPROTEINEMIAS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 33845680179     PISSN: 17402522     EISSN: 10292357     Source Type: Journal    
DOI: 10.1080/17402520600876945     Document Type: Article

References (95)

1. Alverson DC, Chase HP. 1977. Systemic lupus erythematosus in childhood presenting as hyperlipoproteinemia. J Pediatr 91:72-75.
2. Appel GB, Blum CB, Chien S, et al. 1985. The hyperlipidemia of the nephrotic syndrome. Relation to plasma albumin concentration, oncotic pressure, and viscosity. N Engl J Med 312(24):1544-1548.
3. Aronson D, Sella R, Sheikh-Ahmad M, et al. 2004. The association between cardiorespiratory fitness and C-reactive protein in subjects with the metabolic syndrome. J Am Coll Cardiol 44:2003-2007.
4. Asanuma Y, Chung CP, Oeser A, et al. 2006. Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: Relationship to cardiovascular risk factors. J Rheumatol 33(3):539-545.
5. Attman PO, Alaupovic P. 1991. Lipid and apolipoprotein profiles of uremic dyslipoproteinemia - relation to renal function and dialysis. Nephron 57(4):401-410.
6. Bass KM, Newschaffer CJ, Klag MJ, Bush TL. 1993. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med 153:2209-2216.
7. Beaumont JL, Beaumont V. 1977. Autoimmune hyperlipidemia. Atherosclerosis 26:405-418.
8. Beutler BA, Cerami A. 1985. Recombinant interleukin 1 suppresses lipoprotein lipase activity in 3T3-L1 cells. J Immunol 135:3969-3971.
9. Beutler B, Mahoney J, Le Trang N, et al. 1985. Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells. J Exp Med 161:984-995.
10. Borba EF, Bonfa E. 1997. Dyslipoproteinemias in systemic lupus erythematosus: Influence of disease, activity, and anticardiolipin antibodies. Lupus 6(6):533-539.
11. Borba EF, Bonfa E. 2001. Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J Rheumatol 28:780-785.
12. Borba EF, Bonfa E, Vinagre CG, et al. 2000. Chylomicron metabolism is markedly altered in systemic lupus erythematosus. Arthritis Rheum 43:1033-1040.
13. Brown WV. 1994. Lipoprotein disorders in diabetes mellitus. Med Clin North Am 78:143-161.
14. Bruce IN. 2005. 'Not only. . .but also': Factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology (Oxford) 44(12):1492-1502.
15. Bruce IN, Urowitz MB, Gladman DD, et al. 1999. Natural history of hypercholesterolemia in systemic lupus erythematosus. J Rheumatol 26:2137-2143.
16. de Carvalho JF, Borba EF, Viana VS, et al. 2004. Anti-lipoprotein lipase antibodies: A new player in the complex atherosclerotic process in systemic lupus erythematosus? Arthritis Rheum 50(11):3610-3615.
17. Castelli WP, Garrison RJ, Wilson PW, et al. 1986. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham study. JAMA 256:2835-2838.
18. Castelli WP. 1988. Cardiovascular disease in women. Am J Obstet Gynecol 158:1553-1560.
19. Castelli WP. 1986. The triglyceride issue: A view from Framingham. Am Heart J 112:432-437.
20. Chait A, Brazg RL, Tribble DL, et al. 1993. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 94:350-356.
21. Deckelbaum RJ, Granot E, Oschry Y, et al. 1984. Plasma triglyceride determines structure-composition in low and high density lipoproteins. Arteriosclerosis 4:225-231.
22. Delgado AJ, Kumar S, Isenberg DA. 2003. Cross-reactivity between anti-cardiolipin, anti-high-density lipoprotein and anti-apolipoprotein A-I IgG antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology 42:893-899.
23. Dinu AR, Merrill JT, Shen C, et al. 1998a. Frequency of antibodies to the cholesterol transport protein apolipoprotein A1 in patients with SLE. Lupus 7:355-360.
24. Dinu AR, Merrill JT, Sutton-Tyrell K, et al. 1998b. Autoantibodies to apolipoprotein A1 (APOA1) in an SLE population: Relationship to HDL levels and to carotid atherosclerosis by ultrasound assessment. Arthritis Rheum 41(Suppl):S139.
25. Enholm C, Aho K, Huttunen JK, et al. 1982. Effect of interferon on plasma lipoproteins and on the activity of postheparin lipases. Arteriosclerosis 2(1):69-73.
26. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. 2001. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 44:2331-2337.
27. Ettinger WH, Hazzard WR. 1988. Elevated apolipoprotein-B levels in corticosteroid-treated patients with systemic lupus erythematosus. J Clin Endocrinol Metab 67:425-428.
28. Ettinger WH, Goldberg AP, Applebaum-Bowden D, Hazzard WR. 1987. Dyslipoproteinemia in systemic lupus erythematosus. Effects of corticosteroids. Am J Med 83:503-508.
29. Feinberg B, Kurzrock R, Talpaz M, et al. 1988. A phase I trial of intravenously-administered recombinant tumor necrosis factoralpha in cancer patients. J Clin Oncol 6(8):1328-1334.
30. Festa A, D'Agostino R Jr, Howard G, et al. 2000. Chronic subclinical inflammation as part of the insulin resistance syndrome: The insulin resistance atherosclerosis study (IRAS). Circulation 102:42-47.
31. Fluiter K, Vietsch H, Biessen EA, et al. 1996. Increased selective uptake in vivo and in vitro of oxidized cholesteryl esters from high-density lipoprotein by rat liver parenchymal cells. Biochem J 319:471-476.
32. Fredrikson GN, Hedblad B, Nilsson JA, et al. 2004. Association between diet, lifestyle, metabolic cardiovascular risk factors, and plasma C-reactive protein levels. Metabolism 53:1436-1442.
33. Frostegard J. 2005. SLE, atherosclerosis and cardiovascular disease. J Intern Med 257(6):485-495.
34. Frostegard J, Svenungsson E, Wu R, et al. 2005. Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis Rheum 52(1):192-200.
35. Gabay C, Kushner I. 1999. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340(6):448-454.
36. George J, Harats D, Gilburd B, et al. 1999. Atherosclerosis-related markers in systemic lupus erythematosus patients: The role of humoral immunity in enhanced atherogenesis. Lupus 8:220-226.
37. Gerstein HC, Thorpe KE, Taylor DW, Haynes RB. 2002. The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas - a randomized trial. Diabetes Res Clin Pract 55:209-219.
38. Glueck CJ, Levy RI, Glueck HI, et al. 1969a. Acquired type I hyperlipoproteinemia with systemic lupus erythematosus, dysglobulinemia and heparin resistance. Am J Med 47(2):318-324.
39. Glueck CJ, Kaplan AP, Levy RI, et al. 1969b. A new mechanism of exogenous hyperglyceridemia. Ann Intern Med 71(6):1051-1062.
40. Goldberg IJ. 1996. Lipoprotein lipase and lipolysis: Central roles in lipoprotein metabolism and atherogenesis. J Lipid Res 37:693-707.
41. Gordon T, Castelli WP, Hjortland MC, et al. 1977. High density lipoprotein as a protective factor against coronary heart disease. Am J Med 62:707-714.
42. Grau AJ, Buggle F, Becher H, et al. 1996. The association of leukocyte count, fibrinogen and C-reactive protein with vascular risk factors and ischemic vascular diseases. Thromb Res 82:245-255.
43. Hahn BH. 2003. Systemic lupus erythematosus and accelerated atherosclerosis. N Engl J Med 349(25):2379-2380.
44. Heinecke JW. 1997. Mechanisms of oxidative damage of low-density lipoprotein in human atherosclerosis. Curr Opin Lipidol 8:268-274.
45. Heiss G, Tamir I, Davis CE, et al. 1980. Lipoprotein-cholesterol distribution in selected North American populations: The lipid research clinics program prevalence study. Circulation 61:302-315.
46. Henkin Y, Como JA, Oberman A. 1992. Secondary dyslipidemia. Inadvertent effects of drugs in clinical practice. JAMA 267:961-968.
47. Hodis HN, Quismorio FP, Wickham E, Blankenhorn DH. 1993. The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus. J Rheumatol 20:661-665.
48. Hooks JJ, Jordan GW, Cupps T, et al. 1982. Multiple interferons in the circulation of patients with systemic lupus erythematosus and vasculitis. Arthritis Rheum 25:396-400.
49. Hyka N, Dayer JM, Modoux C, et al. 2001. Apolipoprotein A-I inhibits the production of interleukin-1_ and tumor necrosis factor-_ by blocking contact-mediated activation of monocytes by T lymphocytes. Blood 97:2381-2389.
50. Ilowite NT, Samuel P, Ginzler E, et al. 1988. Dyslipoproteinemia in pediatric systemic lupus erythematosus. Arthritis Rheum 31:859-863.
51. Inoue S, Egashira K, Ni W, et al. 2002. Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of establish atherosclerosis in apolipoprotein E-knockout mice. Circulation 106:2700-2706.
52. Jacobs DR Jr, Mebane IL, Bangdiwala SI, et al. 1990. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: The follow-up study of the lipid research clinics' prevalence study. Am J Epidemiol 131:32-47.
53. Jialal I, Devaraj S, Venugopal SK. 2004. C-reactive protein: Risk marker or mediator in atherothrombosis? Hypertension 44:6-11.
54. Kannel WB, Hjortland MC, McNamara PM, et al. 1976. Menopause and risk of cardiovascular disease. The Framingham study. Ann Intern Med 85:447-452.
55. Kavanaugh A, Adams-Huet B, Jain R, Denke M, McFarlin J. 1997. Hydroxychloroquine effects on lipoprotein profiles (the HELP trial): A double-blind, randomized, placebo-controlled, pilot study in patients with systemic lupus erythematosus. J Clin Rheumatol 3:3-8.
56. Kobayashi K, Matsuura E, Liu Q, et al. 2001. A specific ligand for beta(2)-glycoprotein I mediates autoantibody-dependent uptake of oxidized low density lipoprotein by macrophages. J Lipid Res 42(5):697-709.
57. Kobayashi K, Kishi M, Atsumi T, et al. 2003. Circulating oxidized LDL forms complexes with beta2-glycoprotein I: Implication as an atherogenic autoantigen. J Lipid Res 44(4):716-726.
58. Lahita RG, Rivkin E, Cavanagh I, et al. 1993. Low levels of total cholesterol, high-density lipoprotein, and apolipoprotein A1 in association with anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 36:1566-1574.
59. Lee AB, Godfrey T, Rowley KG, et al. 2006. Traditional risk factor assessment does not capture the extent of cardiovascular risk in systemic lupus erythematosus. Intern Med J 36(4):237-243.
60. Leong KH, Koh ET, Feng PH, Boey ML. 1994. Lipid profiles in patients with systemic lupus erythematosus. J Rheumatol 21:1264-1267.
61. Libby P. 2002. Inflammation in atherosclerosis. Nature 420(6917):868-874, 19-26 December.
62. Lopez LR, Simpson DF, Hurley BL, et al. 2005. OxLDL/{beta} 2GPI complexes and autoantibodies in patients with systemic lupus erythematosus, systemic sclerosis, and antiphospholipid syndrome: Pathogenic implications for vascular involvement. Ann N Y Acad Sci 1051:313-322.
63. Lopez LR, Salazar-Paramo M, Palafox-Sanchez C, et al. 2006. Oxidized low-density lipoprotein and beta2-glycoprotein I in patients with systemic lupus erythematosus and increased carotid intima-media thickness: Implications in autoimmune-mediated atherosclerosis. Lupus 15(2):80-86.
64. MacGregor AJ, Dhillon VB, Binder A, et al. 1992. Fasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosus. Ann Rheum Dis 51:152-155.
65. Manzi S, Meilahn EN, Rairie J, et al. 1997. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham study. Am J Epidemiol 145:408-415.
66. Manzi S, Selzer F, Sutton-Tyrrel K, et al. 1999. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 42:51-60.
67. Maury CPJ, Teppo AM. 1989. Tumor necrosis factor in the serum of patients with systemic lupus erythematosus. Arthritis Rheum 32:146-150.
68. Navab M, Ananthramaiah GM, Reddy ST, et al. 2004. The oxidation hypothesis of atherogenesis: The role of oxidized phospholipids and HDL. J Lipid Res 45:993-1007.
69. Parthasarathy S, Barnett J, Fong LG. 1990. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1044:275-283.
70. Pauciullo P, De Simone B, Rubba P, et al. 1986. A case of association between type I hyperlipoproteinemia and systemic lupus erythematosus (SLE). Effects of steroid treatment. J Endocrinol Invest 9:517-520.
71. Petri M, Perez-Gutthann S, Spence D, et al. 1992. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 93:513-519.
72. Petri M, Lakata C, Magder L, Goldman D. 1994. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: A longitudinal data analysis. Am J Med 96:254-259.
73. Powrie JK, Shojaee-Moradie F, Watts GF, et al. 1993. Effects of chloroquine on the dyslipidemia of non-insulin-dependent diabetes mellitus. Metabolism 42:415-419.
74. Rahman P, Gladman DD, Urowitz MB, et al. 1999. The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. J Rheumatol 26:325-330.
75. Reckless J, Rubin EM, Verstuyft JB, et al. 1999. Monocyte chemoattractant protein-1 but not tumor necrosis factor-alpha is correlated with monocyte infiltration in mouse lipid lesions. Circulation 99:2310-2316.
76. Reichlin M, Fesmire J, Quintero-Del-Rio AI, et al. 2002. Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus. Arthritis Rheum 46(11):2957-2963.
77. Richards GE, Grundy SM, Cooper K. 1989. Influence of plasma triglycerides on lipoprotein patterns in normal subjects and in patients with coronary artery disease. Am J Cardiol 63:1214-1220.
78. Ross R. 1993. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 362(6423):801-809.
79. Ross R. 1999. Atherosclerosis - an inflammatory disease. N Engl J Med 340(2):115-126.
80. Schaefer EJ, et al. 1987. Plasma triglycerides in regulation of HDL-cholesterol levels. Lancet ii:391-392.
81. Semb H, Peterson J, Tavernier J, et al. 1987. Multiple effects of tumor necrosis factor on lipoprotein lipase in vivo. J Biol Chem 262:8390-8394.
82. Shoenfeld Y, Gerli R, Doria A, et al. 2005. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112(21):3337-3347.
83. Sholter DE, Armstrong PW. 2000. Adverse effects of corticosteroids on the cardiovascular system. Can J Cardiol 16:505-511.
84. Spronk PE, Ter Borg EJ, Limburg PC, et al. 1992. Plasma concentration of IL-6 in systemic lupus erythematosus; an indicator of disease activity? Clin Exp Immunol 90:106-110.
85. Stender S, Zilversmit DB. 1981. Transfer of plasma lipoprotein components and plasma proteins into aortas of cholesterol-fed rabbits: Molecular size as a determinant of plasma lipoprotein influx. Arteriosclerosis 1:28-49.
86. Svenungsson E, Jensen-Urstad K, Heimburger M, et al. 2001. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 104:1887-1893.
87. Svenungsson E, Fei GZ, Jensen-Urstad K, et al. 2003a. TNF-alpha: A link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease. Lupus 12(6):454-461.
88. Svenungsson E, Gunnarsson I, Fei GZ, et al. 2003b. Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum 48(9):2533-2540.
89. Tamakoshi K, Yatsuya H, Kondo T, et al. 2003. The metabolic syndrome is associated with elevated circulating C-reactive protein in healthy reference range, a systemic low-grade inflammatory state. Int J Obes Relat Metab Disord 27:443-449.
90. Tanaka Y, Saito K, Shirakawa F, et al. 1988. Production of B cell-stimulating factors by B cells in patients of systemic lupus erythematosus. J Immunol 141:3043-3049.
91. Thompson GR, Soutar AK, Spengel FA, et al. 1981. Defects of receptor-mediated low density lipoprotein catabolism in homozygous familial hypercholesterolemia and hypothyroidism in vivo. Proc Natl Acad Sci USA 78(4):2591-2595.
92. Vaarala O, Alfthan G, Jauhiainen M, et al. 1993. Crossreaction between antibodies to oxidised low density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 341:923-925.
93. Van Lenten BJ, Hama SY, de Beer FC, et al. 1995. Antiinflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 96:2758-2767.
94. Wallace DJ, Metzger AL, Stecher VJ, Tumbull BA, Kern PA. 1990. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: Reversal of deleterious effects of steroids on lipids. Am J Med 89:322-326.
95. Wu R, Svenungsson E, Gunnarsson I, et al. 1999. Antibodies against lysophosphatidylcholine and oxidized LDL in patients with SLE. Lupus 8:142-150.